Aspira Women's Health Earnings Call Transcripts
Fiscal Year 2024
-
Q3 2024 saw 4% year-over-year test volume growth and a 2% revenue increase, despite weather disruptions. Secured a $10M ARPA-H grant for EndoInform, gained NY State approval for OvaWatch, and improved gross margin to 60%.
-
Secured $10M ARPA-H funding to accelerate a non-invasive endometriosis diagnostic, targeting commercial launch in two years. Expanded ovarian cancer and endometriosis pipelines leverage AI, protein, and microRNA biomarkers, with a projected $1B+ annual revenue opportunity and strong competitive positioning.
-
Q2 2024 saw record OvaSuite test volumes, a tenfold increase in addressable market, and strong OvaWatch growth. Revenue rose 13% sequentially, with improved sales efficiency and expanded payer coverage. Updated cash use guidance and new financing support near-term operations.